Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.51 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900665 | 1.00 | S1PR5 (0.51) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL20427358 | 1.00 | S1PR5 (0.51) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL20427197 | 0.92 | HRH2 (0.47) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL17834832 | 0.92 | S1PR5 (0.49) | S1PR5S1PR1S1PR3ITGB3ITGA2B | |
| SCHEMBL20426110 | 0.91 | S1PR5 (0.48) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL17834831 | 0.91 | S1PR5 (0.49) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL16306062 | 0.90 | S1PR5 (0.48) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL16305732 | 0.90 | S1PR5 (0.48) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL16305731 | 0.90 | S1PR5 (0.47) | S1PR5HRH2HRH1S1PR1S1PR3 | |
| SCHEMBL16305728 | 0.90 | S1PR5 (0.47) | S1PR5HRH2HRH1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | S1PR5 939/4885HRH2 469/4885HRH1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.